Clinical Trials
423 trialsCLARA
Hospices Civils de Lyon
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CINC424A2X01B Rollover Protocol
Novartis
A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors
City of Hope Medical Center
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
SystImmune Inc.
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
National Cancer Institute (NCI)
CART123
Children's Hospital of Philadelphia
RAVEN
UNC Lineberger Comprehensive Cancer Center
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
Wake Forest University Health Sciences
FORWARD
CareDx
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Ruijin Hospital
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Servier
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
M.D. Anderson Cancer Center
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
Beijing GoBroad Hospital
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Children's Oncology Group
AML-FITNESS
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
M.D. Anderson Cancer Center
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Dana-Farber Cancer Institute
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
City of Hope Medical Center
Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
M.D. Anderson Cancer Center
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
M.D. Anderson Cancer Center
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
REVEAL-ND NPM1
Syndax Pharmaceuticals
Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
FT-RIC-HAPLO
Institut Paoli-Calmettes
The Oronasal Microbiota in Pediatric Oncology Patients
St. Jude Children's Research Hospital
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Massachusetts General Hospital
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
PedAL BCU, LLC
Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome
Thomas Jefferson University
MOMENTUM
AstraZeneca
Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Masonic Cancer Center, University of Minnesota
Digital Structured Assessment in Older Patients With Acute Leukemia: Clinical Impact
Fundación para la Investigación Biosanitaria del Principado de Asturias